On The Therapeutic Potential of Tocilizumab in IL-6-Positive Cancers
IL-6 is an immune signaller misappropriated by many cancer types to engender immune senescence and proliferative auto-signalling. Disrupting this misappropriation can help overcome IL-6-positive cancers.
On the Limitations of Standard-of-Care and the Potential of Integrative Therapy
Standard-of-care for most cancers has remained largely stagnant and is commonly faced with the issues of severe side effects and recurrence. A holistic approach to integrative therapy can be used to make up for these shortcomings.
Cedric L. Marquard
